Study Boasts Taribavirin Advantage Over Ribavirin for HCV Treatment | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Development of Two HCV Experimental Drugs Halted

Back to News Homepage
Next

Achillion Kicks Off Dosing Trial for Hepatitis C Drug

Study Boasts Taribavirin Advantage Over Ribavirin for HCV Treatment

The Editors at Hepatitis Central
September 29, 2010

Print this page

Previously known as viramidine, taribavirin is less able to enter red blood cells than ribavirin. When substituted for ribavirin during Hepatitis C combination therapy, researchers found that appropriate dosing of taribavirin reduced the anemia rate while increasing the treatment’s efficacy.

Taribavirin offers a safe, effective alternative for chronic hepatitis C

Public release date: 22-Sep-2010

Weight-based taribavirin reduces anemia, increases sustained virologic response
Researchers at Cedars-Sinai Medical Center and 50 other centers found that weight-based dosing of taribavirin reduces rates of anemia while increasing sustained virologic response (SVR) in patients with chronic hepatitis C (HCV). Full details of this study are available in the October issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

Chronic HCV is typically treated with ribavirin (RBV). When used in combination with peginterferon alfa (peg-IFN), RBV significantly enhances on-treatment virologic response and reduces relapse. However, RBV, particularly the combination of interferon and RBV, is associated with hemolytic anemia, a significant toxicity resulting from the accumulation of RBV in red blood cells. Taribavirin (TBV), formerly known as viramidine, is a nucleoside analog and oral pro-drug of RBV that is less able to enter red blood cells, and should therefore be associated with significantly less anemia.

Continue reading this entire article:
http://www.eurekalert.org/pub_releases/2010-09/w-toa092210.php

No Comments - be the first!
Share
Share
Previous

Development of Two HCV Experimental Drugs Halted

Back to News Homepage
Next

Achillion Kicks Off Dosing Trial for Hepatitis C Drug

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.